Akebia Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| AKB-097 Phase 2 Rare Kidney Disease Basket Study Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Vafseo Net Product Revenues Quarterly15.8MTarget: Continued sequential growth to offset Auryxia generic erosion
Auryxia Net Product Revenues Quarterly36.2MTarget: Stabilization despite generic competition from Teva and authorized generics
Vafseo Prescriber Count Quarterly1KTarget: Expansion beyond initial 1,025 prescribers
Cash and Cash Equivalents Quarterly162.6MTarget: Maintain runway of at least two years of operations
Watch Items
- Auryxia Generic ErosionTrigger: Auryxia quarterly revenue falling below $25 millionAction: Accelerate Vafseo commercialization and optimize cost structure to preserve cash runway
- Vafseo TDAPA Expiration PreparationTrigger: Approaching December 31, 2026 (TDAPA expiration date)Action: Finalize commercial pricing strategies to align Vafseo with ESA-like pricing levels post-TDAPA
- Praliciguat Phase 2 FSGS Trial EnrollmentTrigger: Slower than expected patient enrollment (target ~60 patients)Action: Expand clinical trial sites and enhance investigator outreach
Research as of 19 Jun 2026